Bottle of Lies: Ranbaxy and the Dark Side of Indian Pharma



Bottle of Lies: Ranbaxy and the Dark Side of Indian Pharma

The book that will rock the Indian pharma industry

In 2004, Dinesh Thakur, a senior employee of Ranbaxy, then India’s largest pharma company, discovered a terrible secret. Ranbaxy had been fabricating the test results of its drugs, endangering millions of patients. Thakur resigned and became a whistleblower to the US Food and Drug Administration, one of the regulators Ranbaxy had been lying to, and ultimately brought the multibillion-dollar behemoth to it’s knees. This is the sensational account of the high-stakes chase to bring Ranbaxy to book and fall from grace of one of corporate India’s biggest success stories.

But the rot in Indian pharma isn’t confined to Ranbaxy alone. In this book, investigative journalist Katherine Eban relies on over 20,000 FDA documents and interviews with over 240 people to show how fraud and trickery are entrenched deeply in much of the industry in India and raises troubling questions of some of its biggest names – Wockhardt, Dr Reddy’s, Glenmark and RPG Life Sciences.

Filled with shocking and eye-opening details, this book lays bare the ugly truth of Indian pharma. It will make you view every pill you take with foreboding and suspicion.
 
 
About The Author

Katherine Eban, an investigative journalist, is a Fortune magazine contributor and Andrew Carnegie fellow. She has also written for Vanity Fair, the New York Times, Self, The Nation, and the New York Observer, and other publications. She is the author of Dangerous Doses: A True Story of Cops, Counterfeiters and the Contamination of America’s drug supply, and lectures frequently on the topic of pharmaceutical integrity. Educated at Brown University and Oxford, where she was a Rhodes scholar, she lives in New York City with her husband and two daughters.
 
 
 
 
 
 
 
 
A New Book Argues That Generic Drugs Are Poisoning Us

Book Review by David Dobbs in “The New York Times”

BOTTLE OF LIES : Ranbaxy and The Dark Side of Indian Pharma

By Katherine Eban


 
 
Who would ever guess that Gandhi helped start an industry whose corruption now plagues us all? Yet here he is, early in Katherine Eban’s “Bottle of Lies,” barefoot in his Ahmedabad ashram, urging the chemist Khwaja Abdul Hamied (a fellow Indian nationalist) to copy Western drugs as a way to bring affordable medicine to India’s masses. Thus the generic drug industry began.

 
 

At first, things went nicely. Hamied’s business, Cipla, founded in 1935, quickly grew adept at reverse-engineering
drug formulas, and by midcentury it was supplying India and other countries with low-cost versions of important Western medicines. In the 1980s, when the United States began allowing the import of such generics, Cipla and other generic makers became heroes to critics of Big Pharma. This admiration grew when Cipla revealed in the early 2000s that it would provide an H.I.V. drug that cost roughly a dollar a day — about 4 percent of Big Pharma’s price — to tens of millions of Africans who would otherwise go untreated. Gandhi’s dream had gone global.
 
 

Alas, Cipla’s triumph is pretty much the last feel-good moment in this lively but dark story. Cipla, almost a tenth the size of Merck, has kept its nose clean. But much of the wider generics industry is harming and sometimes killing patients by making drugs quick and dirty and erecting facades of legitimacy to fool regulators. This booming industry, with most production coming out of lightly regulated plants in India and China, is pumping bad medicine into unsuspecting patients in every corner of the globe.
 
 

Eban’s gripping book lays bare how Gandhi’s well-intentioned local action became hellish global fraud. At once a tale of tragic heroism and a sprawling but concisely written epic, it shows how an industry founded to counteract Big Pharma is now uneasily merging with it, creating a two-headed monster whose tentacles ensnare both hapless victims and would-be regulators.
 
 

The book’s central thread is a David and Goliath whistle-blower story, as a young engineer and executive named Dinesh Thakur tries to stop Ranbaxy Laboratories, the Indian generics giant that employs him, from continuing (and covering up) its careless drug manufacture. A native of India who entered pharmaceuticals after doing graduate work in the United States, Thakur has a sharp sense of ethics and a meticulous way of thinking that seem well suited to his job. For the key to safe manufacture is to closely monitor and control every aspect of drug production — and document everything — to ensure and show that each pill, vial or capsule accurately reproduces the formula. “All medicines are poisonous,” observes Bright Simons, the Ghanaian creator of a drug verification program. “It’s only under the most controlled conditions that they do good.”
 
 


When Thakur learns that Ranbaxy is cutting corners and hiding it, he is horrified. His horror doubles when he learns his company is sending faulty drugs to Africa, where they’ll likely go undetected. Ultimately he quits — and then, aware he’s taking a big personal risk, spills everything he knows to the F.D.A.
 
 
 
 
Eban skilfully unspools the slow, intricate, cat-and-mouse investigation that follows, as well as an armed raid of corporate headquarters (“Step away from your desk”), the discovery of astounding levels of deceit and damage, and finally a three-front legal battle, as Ranbaxy fights the F.D.A., the United States attorney Rod Rosenstein and the lawyer Thakur retains so he won’t get skinned alive. This narrative, spread episodically throughout, is riveting and increasingly foreboding. Occasionally a sentence is flat-footed or unfresh. But Eban’s pacing, along with a structure that makes this astonishingly complex story easy to follow, gives the book a rough, unforced elegance. Her portrayal of Thakur’s plight will set crawling the skin of anyone who has alerted regulators to horrid misdeeds only to find those regulators not just timid but outright protective of the villains.
 
 

Thakur’s story stuns with how utterly corrupt an entire company can become. Both his and the book’s broader account of the industry, meanwhile, show how a quieter sort of corruption — an erosion of will and mission — has neutralized the industry’s overseers.
 
 

The F.D.A. long regulated the American industry by making surprise site visits to inspect production and testing rooms and exhaustively checking records. By Eban’s account, this worked fairly well in the United States. But it failed spectacularly in the Indian and then Chinese factories that, starting in the 1980s, were making and exporting more and more generics.
 
 


Unlike American plants, which matured in an environment where constant oversight made shortcuts risky, the Indian industry evolved in a culture in which outwitting inefficient bureaucracies was an essential skill. There the most rational approach was to stress speed and production over accuracy and quality — and deal with the occasional inspector with some sleight of hand and greasing of palm.
 
 
 
 
The F.D.A. was utterly unprepared for this, and largely blind as well to the implications of both its own and the Indian industry’s cultural assumptions. Lost, it tried to get by, Eban writes, with “a system built on wishful thinking and infrequent scrutiny.” Especially early on, inspections of foreign factories were rare — as few as 100 a year in the 1990s, which worked out to a rate of one inspection per plant every 11 years. These inspections were seldom surprises, because the State Department, valuing good relations over good drugs, asked the F.D.A. to give plants several weeks’ notice. So instead of flashing a badge and roaming at will, inspectors would be fetched from their hotels by drug-company cars and escorted into receptions and plant tours hosted by up to a dozen corporate officers flown in from headquarters. Meanwhile, as more aggressive inspectors eventually learned, a second set of corporate officers would be in back rooms and production areas destroying failed quality test results and fabricating documents showing successful tests. Some plants even built, just for these inspections, fake production and testing areas that were kept pristine while the drugs were made in substandard conditions elsewhere.
 
 

These high jinks read like farce but hit like poison, as tainted drugs daily enter patients’ bloodstreams worldwide. In Africa, which the companies consider the safest place to send faulty drugs, doctors regularly find that drugs for AIDS, bacterial infections and other conditions are underpowered. In the United States, imports from
India now make up 40 percent of all generics used, and 80 percent of the active ingredients used in both generic and brand-name medications come from India and China. In 2007, when scores of kidney patients across the United States died from allergic reactions after dialysis, experts traced the cause to a contaminant in the blood thinner heparin provided by a Chinese plant contracted by Baxter, the leading American supplier. The F.D.A. had never inspected this plant. Someone there, it seems, had intentionally added a chemical to stretch the drug’s yield and profitability.
 
 

The prognosis is grim. The World Health Organization has established, and some plants follow, a definition of “good management practice” for drug manufacture, but no international regulatory body exists to enforce it. The F.D.A. is overmatched and uninspired. And with Big Pharma using saturation advertising to drive demand for its expensive drugs, an overmedicalized society is demanding more and more drugs sooner and cheaper. At the same time, even brand-name companies are increasingly hiring poorly regulated Indian and Asian plants to make their ingredients or formulations — just as the generic industry is being prosecuted for price-fixing. The entire drug supply, as one prominent American cardiologist concluded, is “sick.”
 
 

“Bottle of Lies” is an invaluable exposé, a reportorial tour de force and a well-turned epic. Is it news you can use? I can’t give medical advice. Our best medicines are indeed wondrous; many of us owe our lives to them. But I can relate that Eban quotes inspector after inspector saying that they themselves fill only the most essential prescriptions — and will pay anything to avoid taking a drug made overseas. They’ve seen how those drugs are produced, and they live in fear of them.
 
 

‘Bottle Of Lies’ – Fact Or Propaganda? | Katherine Eban To ET NOW
Allegations of widespread fraud raise questions about the safety of generic drugs made overseas

Bottle of Lies: How Poor FDA Oversight
& Fraud in Generic Drug Industry Threaten Patients’ Health
Why Did the FDA Go Easy on Generic Drug Makers After Inspections Exposed Quality & Safety Concerns?



Leave a Comment

Your email address will not be published. Required fields are marked *

0 thoughts on “Bottle of Lies: Ranbaxy and the Dark Side of Indian Pharma

  • Reply
    plaster
    It's the best time to make some plans for the future and it is time to be happy. I have read this post and if I could I want to suggest you some interesting things or tips. Perhaps you can write next articles referring to this article. I wish to read more things about it!
  • Reply
    zoritoler imol
    Hi, Neat post. There's an issue together with your web site in internet explorer, could test this… IE still is the market leader and a large element of folks will leave out your excellent writing because of this problem.
  • Reply
    graliontorile
    Hey would you mind sharing which blog platform you're using? I'm planning to start my own blog soon but I'm having a difficult time selecting between BlogEngine/Wordpress/B2evolution and Drupal. The reason I ask is because your design seems different then most blogs and I'm looking for something completely unique. P.S Apologies for getting off-topic but I had to ask!
  • Reply
    graliontorile
    naturally like your website but you need to test the spelling on several of your posts. Several of them are rife with spelling problems and I in finding it very troublesome to inform the truth however I will certainly come back again.
  • Reply
    zoritoler imol
    I wish to voice my love for your kindness supporting men and women that really need assistance with your idea. Your very own dedication to getting the message up and down had been especially practical and have usually encouraged others like me to arrive at their desired goals. Your amazing helpful tips and hints means a whole lot to me and far more to my mates. Best wishes; from each one of us.
  • Reply
    zoritoler imol
    You could definitely see your enthusiasm in the work you write. The world hopes for even more passionate writers like you who are not afraid to say how they believe. Always go after your heart.
  • Reply
    zoritoler imol
    whoah this weblog is magnificent i love reading your articles. Stay up the great work! You recognize, many persons are hunting around for this info, you could aid them greatly.
  • Reply
    graliontorile
    Good – I should certainly pronounce, impressed with your website. I had no trouble navigating through all tabs and related info ended up being truly easy to do to access. I recently found what I hoped for before you know it at all. Quite unusual. Is likely to appreciate it for those who add forums or something, site theme . a tones way for your customer to communicate. Nice task.
  • Reply
    zortilonrel
    excellent post, very informative. I wonder why the other specialists of this sector don't notice this. You should continue your writing. I'm sure, you've a great readers' base already!